Solventum Co. (NYSE:SOLV) Shares Sold by HM Payson & Co.

HM Payson & Co. decreased its position in shares of Solventum Co. (NYSE:SOLV) by 6.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,525 shares of the company’s stock after selling 230 shares during the quarter. HM Payson & Co.’s holdings in Solventum were worth $233,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. New York Life Investment Management LLC grew its stake in shares of Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after purchasing an additional 136 shares during the period. Blue Trust Inc. grew its stake in shares of Solventum by 2.1% during the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock worth $549,000 after purchasing an additional 161 shares during the period. MML Investors Services LLC grew its stake in shares of Solventum by 3.2% during the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares during the period. Finally, Savant Capital LLC grew its stake in shares of Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock worth $259,000 after purchasing an additional 233 shares during the period.

Solventum Price Performance

SOLV stock opened at $77.96 on Monday. The business has a 50 day moving average price of $73.65 and a 200 day moving average price of $70.71. The stock has a market cap of $13.49 billion and a price-to-earnings ratio of 28.35. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SOLV. Bank of America raised their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Morgan Stanley increased their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group increased their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. Mizuho increased their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Finally, Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.